Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.3.2.24 - (E3-independent) E2 ubiquitin-conjugating enzyme

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma of Lung
UBE2V2 Positively Correlates With PD-L1 Expression and Confers Poor Patient Survival in Lung Adenocarcinoma.
Anemia
UBE2O remodels the proteome during terminal erythroid differentiation.
Autoimmune Diseases
Variants on the UBE2L3-YDJC autoimmune disease risk haplotype increase UBE2L3 gene expression by modulating CTCF and YY1 binding.
Breast Neoplasms
UBE2O promotes the proliferation, EMT and stemness properties of breast cancer cells through the UBE2O/AMPK?2/mTORC1-MYC positive feedback loop.
Carcinogenesis
A new duet in cancer biology: AMPK the typical and UBE2O the atypical.
A UBE2O-AMPK?2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy.
UBE2O promotes the proliferation, EMT and stemness properties of breast cancer cells through the UBE2O/AMPK?2/mTORC1-MYC positive feedback loop.
UBE2O targets Mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance.
Carcinoma
Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma.
The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma.
UBE2O Promotes Progression and Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.
[Roles of hMMS2 gene in reversing the oxaliplatin tolerance of human colon carcinoma cells].
Carcinoma, Hepatocellular
Overexpression of ubiquitin-conjugating enzyme E2 L3 in hepatocellular carcinoma potentiates apoptosis evasion by inhibiting the GSK3?/p65 pathway.
Prognostic value of ubiquitin-conjugating enzyme E2 S overexpression in hepatocellular carcinoma.
Stabilization of E2-EPF UCP protein is implicated in hepatitis B virus-associated hepatocellular carcinoma progression.
Carcinoma, Renal Cell
Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma.
Carcinoma, Squamous Cell
UBE2O Promotes Progression and Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.
Colorectal Neoplasms
[Roles of hMMS2 gene in reversing the oxaliplatin tolerance of human colon carcinoma cells].
Diabetes Mellitus, Type 2
A muscle-specific UBE2O/AMPK?2 axis promotes insulin resistance and metabolic syndrome in obesity.
Diabetes, Gestational
Putative association between UBE2E2 polymorphisms and the risk of gestational diabetes mellitus.
Esophageal Neoplasms
Role of interleukin 1 beta in esophageal squamous cell carcinoma.
The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma.
Glioma
Ectopic High Expression of E2-EPF Ubiquitin Carrier Protein Indicates a More Unfavorable Prognosis in Brain Glioma.
Hepatitis B
Stabilization of E2-EPF UCP protein is implicated in hepatitis B virus-associated hepatocellular carcinoma progression.
Infections
The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis.
Ubiquitin-Conjugating Enzyme E2 L3 is Downregulated by the Chikungunya Virus nsP2 Protease.
Intellectual Disability
A novel UBE2A mutation causes X-linked intellectual disability type Nascimento.
Leukemia
Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset.
Lung Neoplasms
Epigenome-wide DNA methylation signature of benzo[a]pyrene exposure and their mediation roles in benzo[a]pyrene-associated lung cancer development.
UBE2O targets Mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance.
Metabolic Syndrome
A muscle-specific UBE2O/AMPK?2 axis promotes insulin resistance and metabolic syndrome in obesity.
Multiple Myeloma
The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis.
Neoplasm Metastasis
A UBE2O-AMPK?2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy.
E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis.
Stabilization of E2-EPF UCP protein is implicated in hepatitis B virus-associated hepatocellular carcinoma progression.
UBE2O promotes the proliferation, EMT and stemness properties of breast cancer cells through the UBE2O/AMPK?2/mTORC1-MYC positive feedback loop.
Neoplasms
A new duet in cancer biology: AMPK the typical and UBE2O the atypical.
A UBE2O-AMPK?2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy.
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
An Oncogenic Role for the Ubiquitin Ligase UBE2O by Targeting AMPK-?2 for Degradation.
Autodeubiquitination Protects the Tumor Suppressor BAP1 from Cytoplasmic Sequestration Mediated by the Atypical Ubiquitin Ligase UBE2O.
Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma.
Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset.
E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis.
Egr-1 and serum response factor are involved in growth factors- and serum-mediated induction of E2-EPF UCP expression that regulates the VHL-HIF pathway.
Mechanism of muscle protein degradation induced by a cancer cachectic factor.
Prognostic value of ubiquitin-conjugating enzyme E2 S overexpression in hepatocellular carcinoma.
Role of interleukin 1 beta in esophageal squamous cell carcinoma.
Stabilization of E2-EPF UCP protein is implicated in hepatitis B virus-associated hepatocellular carcinoma progression.
The Positive Correlations between the Expression of Histopathological Ubiquitin-Conjugating Enzyme 2O Staining and Prostate Cancer Advancement.
The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis.
UBE2D3 Activates SHP-2 Ubiquitination to Promote Glycolysis and Proliferation of Glioma via Regulating STAT3 Signaling Pathway.
UBE2O Promotes Progression and Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.
UBE2O promotes the proliferation, EMT and stemness properties of breast cancer cells through the UBE2O/AMPK?2/mTORC1-MYC positive feedback loop.
UBE2O targets Mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance.
Obesity
A muscle-specific UBE2O/AMPK?2 axis promotes insulin resistance and metabolic syndrome in obesity.
Osteosarcoma
Ubiquitin-conjugating enzyme UBE2O regulates cellular clock function by promoting the degradation of the transcription factor BMAL1.
Ovarian Neoplasms
UBE2N Regulates Paclitaxel Sensitivity of Ovarian Cancer via Fos/P53 Axis.
Prostatic Neoplasms
Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset.
The Positive Correlations between the Expression of Histopathological Ubiquitin-Conjugating Enzyme 2O Staining and Prostate Cancer Advancement.
Skin Abnormalities
A novel UBE2A mutation causes X-linked intellectual disability type Nascimento.
Squamous Cell Carcinoma of Head and Neck
UBE2O Promotes Progression and Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.